TMO Stock Forecast 2025-2026
Distance to TMO Price Targets
TMO Price Momentum
10 Quality Stocks Worth Considering Now
Researching Thermo Fisher (TMO) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on TMO and similar high-potential opportunities.
Latest TMO Stock Price Targets & Analyst Predictions
Based on our analysis of 33 Wall Street analysts, TMO has a bullish consensus with a median price target of $665.00 (ranging from $560.77 to $767.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $513.67, the median forecast implies a 29.5% upside. This outlook is supported by 25 Buy, 6 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Conor McNamara at RBC Capital, projecting a 49.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TMO Analyst Ratings
TMO Price Target Range
Latest TMO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TMO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 4, 2025 | Citigroup | Patrick Donnelly | Neutral | Maintains | $570.00 |
| Feb 3, 2025 | Scotiabank | Sung Ji Nam | Sector Perform | Maintains | $650.00 |
| Feb 3, 2025 | Raymond James | Andrew Cooper | Outperform | Reiterates | $667.00 |
| Jan 31, 2025 | Citigroup | Patrick Donnelly | Neutral | Maintains | $650.00 |
| Jan 31, 2025 | UBS | Dan Leonard | Buy | Maintains | $715.00 |
| Jan 31, 2025 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $680.00 |
| Jan 31, 2025 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $678.00 |
| Jan 13, 2025 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $647.00 |
| Dec 23, 2024 | Scotiabank | Sung Ji Nam | Sector Perform | Initiates | $605.00 |
| Dec 13, 2024 | B of A Securities | Derik De Bruin | Buy | Maintains | $660.00 |
| Oct 24, 2024 | Baird | Catherine Schulte | Outperform | Maintains | $622.00 |
| Oct 24, 2024 | Bernstein | Eve Burstein | Market Perform | Maintains | $620.00 |
| Oct 24, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $718.00 |
| Oct 24, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $620.00 |
| Oct 24, 2024 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $660.00 |
| Oct 24, 2024 | Stifel | Daniel Arias | Buy | Maintains | $665.00 |
| Oct 23, 2024 | Barclays | Luke Sergott | Equal-Weight | Maintains | $610.00 |
| Oct 15, 2024 | Barclays | Luke Sergott | Equal-Weight | Maintains | $620.00 |
| Oct 14, 2024 | Redburn Atlantic | Buy | Initiates | $680.00 | |
| Oct 1, 2024 | Stephens & Co. | Jacob Johnson | Overweight | Initiates | $680.00 |
Thermo Fisher Scientific Inc. (TMO) Competitors
The following stocks are similar to Thermo Fisher based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Thermo Fisher Scientific Inc. (TMO) Financial Data
Thermo Fisher Scientific Inc. has a market capitalization of $193.79B with a P/E ratio of 31.1x. The company generates $42.88B in trailing twelve-month revenue with a 14.8% profit margin.
Revenue growth is +4.7% quarter-over-quarter, while maintaining an operating margin of +19.4% and return on equity of +13.1%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Thermo Fisher Scientific Inc. (TMO) Business Model
About Thermo Fisher Scientific Inc.
Provides essential tools for life sciences and healthcare.
The company generates revenue by offering a wide range of laboratory products, analytical instruments, and software solutions tailored for the life sciences, biotechnology, pharmaceutical, and healthcare sectors. Its business model is bolstered by strategic acquisitions and collaborations that enhance its market presence and service offerings.
Thermo Fisher Scientific operates in over 50 countries and is recognized for its innovative technologies in areas such as DNA sequencing, clinical diagnostics, and environmental monitoring, making it a key player in scientific research and health improvement.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
125,000
CEO
Mr. Marc N. Casper
Country
United States
IPO Year
1987
Website
www.thermofisher.comThermo Fisher Scientific Inc. (TMO) Latest News & Analysis
Thermo Fisher Scientific has formed a Technology Alliance Agreement with the Chan Zuckerberg Institute to enhance cell visualization technologies, advancing research in disease and treatment.
Thermo Fisher's agreement with the Chan Zuckerberg Institute enhances its position in advanced imaging technologies, potentially driving growth in research funding and demand for innovative products.
Thermo Fisher has launched the Vulcan Automated Lab, aimed at enhancing semiconductor analysis capabilities.
Thermo Fisher's launch of the Vulcan Automated Lab signals innovation in semiconductor analysis, potentially enhancing efficiency and attracting investment in a key growth sector.
Thermo Fisher Scientific Introduces the Vulcan™ Automated Lab to Transform Semiconductor Analysis
9 days agoThermo Fisher Scientific launched the Thermo Scientific Vulcan™ Automated Lab, aimed at improving productivity and reducing costs in semiconductor manufacturing.
Thermo Fisher's launch of the Vulcan™ Automated Lab signals innovation in semiconductor manufacturing, potentially boosting productivity and profitability for clients, impacting TMO's future revenue and market position.
Barron's New-Year Roundtable highlighted 34 dividend picks for 2025, with AdvanSix, Applied Materials, and Salesforce projected to average 28.85% returns. AT&T and Annaly Capital are noted for high yields.
The Roundtable's dividend picks signal potential high returns, attracting income-focused investors. Stocks like AT&T and Annaly Capital provide appealing yields, enhancing portfolio safety and income.
Thermo Fisher Scientific: Strong Q4, Strategic M&A, And Poised For Growth In Life Sciences
21 days agoThermo Fisher Scientific's Q4'24 and FY'24 results surpassed expectations, showing revenue and profit growth. It returned $4.6B to shareholders and aims for 11% earnings CAGR, indicating strong long-term potential.
Thermo Fisher's strong Q4 and FY results, along with significant shareholder returns and strategic growth initiatives, suggest a promising long-term investment opportunity despite weak guidance.
Billionaire investor Daniel Loeb has a diverse investment portfolio and has successfully navigated various market conditions.
Daniel Loeb's reputation and diverse investment experience signal potential insights into market trends, influencing investor confidence and strategies.
Frequently Asked Questions About TMO Stock
What is Thermo Fisher Scientific Inc.'s (TMO) stock forecast for 2025?
Based on our analysis of 33 Wall Street analysts, Thermo Fisher Scientific Inc. (TMO) has a median price target of $665.00. The highest price target is $767.00 and the lowest is $560.77.
Is TMO stock a good investment in 2025?
According to current analyst ratings, TMO has 25 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $513.67. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TMO stock?
Wall Street analysts predict TMO stock could reach $665.00 in the next 12 months. This represents a 29.5% increase from the current price of $513.67. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Thermo Fisher Scientific Inc.'s business model?
The company generates revenue by offering a wide range of laboratory products, analytical instruments, and software solutions tailored for the life sciences, biotechnology, pharmaceutical, and healthcare sectors. Its business model is bolstered by strategic acquisitions and collaborations that enhance its market presence and service offerings.
What is the highest forecasted price for TMO Thermo Fisher Scientific Inc.?
The highest price target for TMO is $767.00 from Conor McNamara at RBC Capital, which represents a 49.3% increase from the current price of $513.67.
What is the lowest forecasted price for TMO Thermo Fisher Scientific Inc.?
The lowest price target for TMO is $560.77 from at , which represents a 9.2% increase from the current price of $513.67.
What is the overall TMO consensus from analysts for Thermo Fisher Scientific Inc.?
The overall analyst consensus for TMO is bullish. Out of 33 Wall Street analysts, 25 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $665.00.
How accurate are TMO stock price projections?
Stock price projections, including those for Thermo Fisher Scientific Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
